AI In Oncology Market Size, Growth & Forecast 2025-2033

The global AI In oncology market size reached USD 1,542.9 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 18,253.8 Million by 2033, exhibiting a growth rate (CAGR) of 30.01% during 2025-2033.

Nov 25, 2025 - Adam Smith

Market Overview:

The AI In oncology market is experiencing rapid growth, driven by increasing volume and complexity of oncological data, accelerating shift towards precision medicine, and rising investment and regulatory support. According to IMARC Group’s latest research publication, “AI In Oncology Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033”, The global AI In oncology market size reached USD 1,542.9 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 18,253.8 Million by 2033, exhibiting a growth rate (CAGR) of 30.01% during 2025-2033.

This detailed analysis primarily encompasses industry size, business trends, market share, key growth factors, and regional forecasts. The report offers a comprehensive overview and integrates research findings, market assessments, and data from different sources. It also includes pivotal market dynamics like drivers and challenges, while also highlighting growth opportunities, financial insights, technological improvements, emerging trends, and innovations. Besides this, the report provides regional market evaluation, along with a competitive landscape analysis.

Download a sample PDF of this report: https://www.imarcgroup.com/ai-in-oncology-market/requestsample

Our report includes:

Growth Factors in the AI In Oncology Market

The exponential growth in the volume and complexity of data generated across the cancer care continuum is a primary catalyst for AI adoption. Modern oncology produces massive datasets from sources like diagnostic imaging (radiology and pathology scans), genomic sequencing, electronic health records (EHRs), and real-world evidence. Analyzing this data is beyond human capacity, making AI indispensable. For instance, the software solutions segment within the AI in oncology market holds the largest share, at approximately 64.34%, highlighting the demand for tools capable of processing this complexity. AI-driven software instantly processes how cancer cells resist anti-cancer medicines, helping to refine drug development and adjust patient-specific drug applications. This integration of multifaceted information allows for unprecedented pattern recognition, crucial for early and precise diagnoses, as well as optimizing personalized treatment strategies, thereby driving market expansion globally.

The global push toward highly personalized and precision oncology is fundamentally powered by AI, acting as a major growth driver. Precision medicine relies on analyzing individual patient data, including genetic, molecular, and environmental factors, to tailor therapeutic interventions. AI algorithms excel at integrating and interpreting diverse data modalities, such as multi-omics data and advanced imaging, to predict treatment response and prognosis for specific patient subsets. Major technology companies and healthcare providers are actively investing in this area; for example, one key industry player recently launched a cloud-based oncology system that combines various patient datasets using generative AI to create clinical report summaries, directly supporting medical decisions in cancer diagnostics. This capability is pivotal for identifying optimal drug candidates and dosages, enhancing efficacy, and reducing the side effects associated with generalized treatment protocols.

Significant financial investment from both the private sector and government initiatives is accelerating the development and clinical translation of AI in oncology. Large technology firms, venture capital, and pharmaceutical companies are allocating substantial capital to AI-focused research and development. This surge in investment is coupled with increasingly supportive regulatory environments. For example, regulatory bodies have granted clearance to platforms like QmTRIAGE, an AI-enabled system for breast cancer screening, demonstrating the increasing willingness of regulators to approve robust, real-world applications. Furthermore, supportive government bodies in regions like North America, which accounts for the largest market share, have implemented strategies to boost the adoption of AI in healthcare, establishing a strong technical foundation and progressive infrastructure essential for evolving sophisticated AI-based algorithms.

Key Trends in the AI In Oncology Market

An emerging trend is the movement toward multimodal AI, which involves simultaneously integrating and analyzing different types of data—such as medical images, genomic sequences, pathology reports, and clinical notes—to generate a holistic diagnostic and prognostic view. This approach surpasses the limitations of single-data analysis by allowing algorithms to learn complex relationships across modalities. For instance, in applications concerning lung cancer, AI tools are accelerating precise staging and automating the time-consuming process of reading pathology slides and CT scans. This trend is central to integrated diagnostics, where AI-powered platforms synthesize complex information to deliver a single, comprehensive insight, which helps clinicians forecast treatment response, adverse effects, and overall prognosis, supporting better and faster clinical decision-making.

AI is transforming the traditionally long and expensive process of oncology drug discovery and development. By using advanced deep learning and machine learning models, researchers can rapidly screen massive chemical libraries, predict the efficacy and toxicity of potential drug candidates, and identify novel therapeutic targets, all with greater speed than conventional methods. Concrete examples include an AI platform introduced by a major cancer research center to assist physicians by summarizing patient histories, identifying optimal matches for clinical trials, and extracting research data. This application of AI-driven optimization is crucial for streamlining patient recruitment, designing adaptive trial protocols, and accelerating the time it takes to bring new, highly-targeted cancer therapies to market for various indications.

The adoption of Explainable Artificial Intelligence (XAI) is a vital trend focused on ensuring transparency and trust in AI systems used in patient care. Oncologists are increasingly demanding systems that not only provide a diagnosis or treatment recommendation but also clearly articulate the underlying reasons for that conclusion. XAI techniques, such as interactive visualization of model decisions and feature importance analysis, are being developed to improve clinical interpretation. This addresses a major barrier to broader adoption: the 'black box' problem of traditional AI. The increased focus on XAI is essential for gaining confidence among healthcare professionals, facilitating regulatory approval, and ensuring that AI is seamlessly integrated into everyday clinical workflows as a trusted, collaborative decision-support tool.

Leading Companies Operating in the Global AI In Oncology Industry:

AI In Oncology Market Report Segmentation:

By Component:

The AI in oncology market is segmented into software solutions, hardware, and services, with software solutions holding the largest market share.

By Cancer Type:

The market analysis includes breast cancer, lung cancer, prostate cancer, colorectal cancer, brain tumor, and others, with breast cancer representing the largest share.

By Treatment Type:

The AI in oncology market is categorized into chemotherapy, radiotherapy, immunotherapy, and others, with chemotherapy having the largest market share.

By Application:

The market is divided into cancer detection, drug discovery, drug development, and others, focusing on various applications of AI in oncology.

Regional Insights:

The AI in oncology market is analyzed by region, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa, with North America being the largest market due to rising cancer incidences and technological advancements.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-201971-6302

More Posts

Fitness goals while learning
Magnetic Rings
Multi-Color Magnetic Wrap
White Magnetic Ring
Lower Secondary Science Tuition